Silver Book Fact

Cancer patients in the U.S. experience greater survival gains than those in European countries, and the value of additional gains exceeds the additional cost of care in the U.S.

Philipson, T, M Eber, D Lakdawalla, M Corral, R Conti, and D Goldman. An Analysis of Whether Higher Health Care Spending is ?Worth it? in the Case of Cancer. Health Affairs. 2012; 31(4): 667-75. http://content.healthaffairs.org/content/31/4/667.abstract

Reference

Title
An Analysis of Whether Higher Health Care Spending is ?Worth it? in the Case of Cancer
Publication
Health Affairs
Publication Date
2012
Authors
Philipson, T, M Eber, D Lakdawalla, M Corral, R Conti, and D Goldman
Volume & Issue
Volume 31, Issue 4
Pages
667-75
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Close to one third of all drugs currently in the biopharmaceutical pipeline are for cancer, with around 5,500 potential first-in-class cancer medicines in development.  
  • Between August 2004 and July 2014, the FDA approved: Six new anticancer therapeutics Five new uses for previously approved anticancer therapeutics Two new uses for imaging agents One new use for a screening test  
  • Incidence rates for colorectal cancer have been decreasing since 1985, from 66 to 52 per 100,000 in 2002.  
  • The 5-year survival rate for prostate cancer has increased from 67% to nearly 100% over the past 20 years.  
  • Surgical biopsy for lumps in the breast was found by one study to cost 2 1/2 to 3 times more than image-guided core-needle biopsy ($698 versus $243).